5至15个脑转移瘤患者初始立体定向放射外科治疗:多机构经验结果
该多机构回顾性研究纳入2089例初始接受立体定向放射外科治疗的脑转移瘤患者,比较1个、2至4个和5至15个转移瘤的结局。5至15个组与2至4个组生存无差异,但远处脑失败累积发生率更高、挽救性立体定向放射外科使用率更低,挽救性全脑放疗无差异。
要点
- 5至15个脑转移瘤患者初始立体定向放射外科治疗后生存与2至4个组相似。
- 5至15个组1年远处脑失败率为50%,高于1个组的30%和2至4个组的41%。
- 5至15个组2年挽救性立体定向放射外科累积发生率为13%,低于1个组的21%和2至4个组的19%。
核心结论
- 初始接受立体定向放射外科治疗的5至15个脑转移瘤患者生存与2至4个脑转移瘤患者相似。
- 5至15个组挽救性立体定向放射外科使用率较低,挽救性全脑放疗率无差异。
研究设计与样本
- 8个学术中心参与的回顾性多机构研究,共纳入2089例初始接受立体定向放射外科治疗的脑转移瘤患者。
- 其中989例(47%)为1个转移瘤,882例(42%)为2至4个,212例(10%)为5至15个。
- 采用Kaplan-Meier法估计总生存并用对数秩检验比较,采用逐步多变量Cox比例风险模型和竞争风险回归模型评估与总生存及远处脑失败累积发生率的关联。
主要发现
- 1个、2至4个和5至15个脑转移瘤组的中位总生存分别为14.6、9.5和7.5个月(对数秩P < .01)。
- 单变量和多变量分析显示2至4个与5至15个脑转移瘤组之间生存无差异。
- 1年远处脑失败率在1个、2至4个和5至15个组分别为30%、41%和50%(Gray's P < .01)。
- 2年挽救性立体定向放射外科累积发生率随脑转移瘤数目增加而降低(1个:21% vs 2至4个:19% vs 5至15个:13%;P < .01),挽救性全脑放疗无差异(1个:12% vs 2至4个:15% vs 5至15个:16%,P = .10)。
- 发生远处脑失败时,1个、2至4个和5至15个组的中位脑转移瘤速度分别为每年3.9、6.1和11.7个新转移灶(P < .01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several studies evaluating stereotactic radiosurgery (SRS) for patients with >4 brain metastases (BM) demonstrated similar outcomes after treatment of 1, 2 to 4, and 5 to 15 BM; others found clinically significant survival decrements in the latter group. In this review of 8 academic centers, we compared outcomes of patients undergoing initial SRS for 1, 2 to 4, and 5 to 15 BM. METHODS AND MATERIALS: A total of 2089 patients treated with initial SRS for BM were included. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Patient and disease characteristics were evaluated for association with OS and cumulative incidence of distant brain failure (DBF) using stepwise multivariable Cox proportional hazards and competing risk regression modeling. RESULTS: In this series, 989 (47%) patients had 1 metastasis, 882 (42%) had 2 to 4 metastases, and 212 (10%) had 5 to 15 metastases treated. Median OS for the 1, 2 to 4, and 5 to 15 BM groups was 14.6, 9.5, and 7.5 months, respectively (log-rank P < .01). Univariate and multivariable analyses revealed no difference in survival between 2 to 4 and 5 to 15 BM. DBF at 1 year was 30%, 41%, and 50%, respectively (Gray's P < .01). Two-year cumulative incidence of salvage SRS decreased with increasing number of BM (1: 21% vs 2-4: 19% vs 5-15: 13%; P < .01), but no difference in salvage whole brain radiation therapy was observed (1: 12% vs 2-4: 15% vs 5-15: 16%, P = .10). At the time of DBF, median brain metastasis velocity was 3.9, 6.1, and 11.7 new metastases per year in the 1, 2 to 4, and 5 to 15 BM groups, respectively (P < .01). CONCLUSIONS: Patients treated with initial SRS for 5 to 15 BM experienced survival similar to that in patients with 2 to 4 BM. Lower rates of salvage SRS were observed in the 5 to 15 BM group, with no difference in rates of salvage whole brain radiation therapy.
引用
- Hughes RT, Masters AH, McTyre ER, et al. Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. Int J Radiat Oncol Biol Phys. 2019. PMID: 30959122. doi:10.1016/j.ijrobp.2019.03.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。